[Appropriate use of Factor VIII for treatment of hemophilia - A consensus conference]

Andalusian Agency for Health Technology Assessment
Record ID 32005000429
Authors' recommendations: Reinforcement of epidemiological surveillance systems and control of already existing haemoderivatives with special emphasis on the possibility of changes occurring in the risk of transmission of different infectious agents.Improvement of healthcare and management information systems regarding haemophilia treatment and the situation of patients.Definition of the measures to be adopted in order to provide the pharmacovigilance systems with information on adverse effects, especially regarding the development of inhibitors.Improvement in prescription and dispensing in accordance with the principles of the correct use of medication and measures to facilitate the rational use of resources.Promote the diffusion of independent, objective information to haemophilic patients about scientific evidence on the effectiveness and viral safety of the different products.
Project Status: Completed
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Drug Administration Schedule
  • Delivery of Health Care
  • Factor VIII
  • Hemophilia A
  • Hemophilia B
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. InnovaciĆ³n, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.